Supernus Pharma (SUPN) Misses Q3 EPS by 32c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts SUPN Hot Sheet
Join SI Premium – FREE
Supernus Pharma (NASDAQ: SUPN) reported Q3 EPS of $0.03, $0.32 worse than the analyst estimate of $0.35. Revenue for the quarter came in at $177.35 million versus the consensus estimate of $172.94 million.
For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MSG Rangers, Huron Consulting to join S&P SmallCap 600
- MSG Rangers and Huron Consulting Group Set to Join S&P SmallCap 600
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
